



Next-Generation HIV Antiretroviral Therapy and Vaccine Candidates

Guest Editors:

Dr. H.M. Manukumar

Institute of Human Virology,
University of Maryland,
Baltimore, MD 21201, USA

Prof. Tomas Hanke

1. Nuffield Department of
Medicine, The Jenner Institute,
University of Oxford, Oxford OX1
2JD, UK
2. International Research Center
of Medical Sciences (IRCMS),
Kumamoto University,
Kumamoto 860-8555, Japan

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editors

Dear Colleagues,

Despite many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. The vaccine development path for the HIV-1 pathogen has been extremely challenging for different reasons, one of them being the pathogen's high antigenic variability and immune evasion. Its high mutation rate allows it to evade immune responses by modifying its target immunogens during the course of infection. Therefore, I would like to encourage the submission of papers to this Special Issue that focus on novel approaches to vaccine development, including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into this Special Issue. Moreover, being focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials.

Dr. H.M. Manukumar

Prof. Tomas Hanke

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com